Time trend in treatment-related deaths of patients with advanced non-small-cell lung cancer enrolled into phase III trials of systemic treatment

Annals of Oncology

Volumn 22, Issue 2, 2011, Pages 376-382

  Fujiwara, Y ^a,b   Hotta, K ^a   di Maio, M ^c   Kiura, K ^a   Takigawa, N ^a   Tabata, M ^a   Tanimoto, M ^a  

^a OKAYAMA UNIVERSITY HOSPITAL   (Japan)

^b Tsuyama Central Hospital   (Japan)

^c NATIONAL CANCER INSTITUTE   (Italy)

Author keywords

Chemotherapy; Lung cancer; Treatment related death

Indexed keywords

CISPLATIN; DOCETAXEL; EPIDERMAL GROWTH FACTOR RECEPTOR KINASE INHIBITOR; GEMCITABINE; NAVELBINE; PACLITAXEL; VASCULOTROPIN ANTIBODY;

ADVANCED CANCER; ARTICLE; BLEEDING; CANCER MORTALITY; CANCER PATIENT; CARDIOVASCULAR DISEASE; CAUSE OF DEATH; CENTRAL NERVOUS SYSTEM DISEASE; COHORT ANALYSIS; DRUG FATALITY; FEBRILE NEUTROPENIA; HUMAN; INCIDENCE; INTERSTITIAL LUNG DISEASE; KIDNEY FAILURE; LUNG DISEASE; LUNG NON SMALL CELL CANCER; MAJOR CLINICAL STUDY; META ANALYSIS; NEPHROTOXICITY; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; SEPSIS; TREND STUDY;

EID: 79251575000     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdq360     Document Type: Article

References (19)

1. Parkin DM, Bray F, Ferlay J et al. Global cancer statistics, 2002. CA Cancer J Clin 2005; 55(2): 74-108.
2. Non-Small Cell Lung Cancer Collaborative Group. Chemotherapy in non-small cell lung cancer: a meta-analysis using updated data on individual patients from 52 randomized clinical trials. BMJ 1995; 311: 899-909.
3. Hotta K, Matsuo K, Ueoka H et al. Meta-analysis of randomized clinical trials comparing cisplatin to carboplatin in patients with advanced non-small-cell lung cancer. J Clin Oncol 2004; 22: 3852-3859.
4. Hotta K, Matsuo K. Long-standing debate on cisplatinversus carboplatin-based chemotherapy in the treatment of advanced non-small-cell lung cancer. J Thorac Oncol 2007; 2: 96.
5. Bunn PA Jr. Chemotherapy for advanced non-small-cell lung cancer: who, what, when, why? J Clin Oncol 2002; 20 (Suppl 18): S23-S33.
6. Hotta K, Fujiwara Y, Matsuo K et al. Recent improvement in the survival of patients with advanced non-small-cell lung cancer enrolled in phase III trials of first-line systemic chemotherapy. Cancer 2007; 109: 939-948.
7. Hotta K, Matsuo K, Ueoka H. Toxicity data in addition to survival data are important in evaluating the applicability of a chemotherapy regimen of advanced non-small-cell lung cancer. Lung Cancer 2005; 49: 277.
8. Ohe Y, Yamamoto S, Suzuki K et al. Risk factors of treatment-related death in chemotherapy and thoracic radiotherapy for lung cancer. Eur J Cancer 2001; 37: 54-63.
9. Pfister DG, Johnson DH, Azzoli CG et al. American Society of Clinical Oncology treatment of unresectable non-small-cell lung cancer guideline: update 2003. J Clin Oncol 2004; 22: 330-353.
10. Yamanaka T, Okamoto T, Ichinose Y et al. Methodological aspects of current problems in target-based anticancer drug development. Int J Clin Oncol 2006; 11: 167-175.
11. Horstmann E, McCabe MS, Grochow L et al. Risks and benefits of phase 1 oncology trials, 1991 through 2002. N Engl J Med 2005; 352: 895-904.
12. Hotta K, Kiura K, Tabata M et al. Interstitial lung disease in patients with nonsmall-cell lung cancer receiving gefitinib: an analysis of risk factors and treatment outcomes in Okayama Lung Cancer Study Group. Cancer J 2005; 11: 417-424.
13. Kudoh S, Kato H, Nishiwaki Y et al. Interstitial lung disease in Japanese patients with lung cancer: a cohort and nested case-control study. Am J Respir Crit Care Med 2008; 177: 1348-1357.
14. Forsythe B, Faulkner K. Overview of the tolerability of gefitinib (IRESSA) monotherapy: clinical experience in non-small cell lung cancer. Drug Saf 2004; 27: 1081-1092.
15. American Thoracic Society/European Respiratory Society international multidisciplinary consensus classification of the idiopathic interstitial pneumonias. Am J Respir Crit Care Med 2002; 165: 277-304.
16. Grande C, Villanueva MJ, Huidobro G et al. Docetaxel-induced interstitial pneumonitis following non-small-cell lung cancer treatment. Clin Transl Oncol 2007; 9: 578-581.
17. Parulekar WR, Eisenhauer EA. Phase I trial design for solid tumor studies of targeted, non-cytotoxic agents: theory and practice. J Natl Cancer Inst 2004; 96: 990-997.
18. Fossella F, Pereira JR, von Pawel J et al. Randomized, multinational, phase III study of docetaxel plus platinum combinations versus vinorelbine plus cisplatin for advanced non-small-cell lung cancer: the TAX 326 Study Group. J Clin Oncol 2003; 21: 3016-3024.
19. Maemondo M, Inoue A, Kobayashi K et al. Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR. N Engl J Med 2010; 362: 2380-2388.